Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says

Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner Ozempic due for a decision in obesity this June, the company is gearing up for a busy second half to the year.

Reaching that untapped market will prove challenging, for sure, but the insulin giant is now in “full go mode” on the promotional front, Novo's Doug Langa, executive vice president for North America, said in an interview.